Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $46.82 in the prior trading day, GSK Plc ADR (NYSE: GSK) closed at $46.69, down -0.28%. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 5.52 million shares were traded. GSK stock price reached its highest trading level at $47.0351 during the session, while it also had its lowest trading level at $46.52.
Ratios:
Our goal is to gain a better understanding of GSK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.73. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.84. In the meantime, Its Debt-to-Equity ratio is 1.10 whereas as Long-Term Debt/Eq ratio is at 0.92.
On April 15, 2025, Exane BNP Paribas started tracking the stock assigning a Neutral rating and target price of $35.25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GSK now has a Market Capitalization of 94464409600 and an Enterprise Value of 202021945344. As of this moment, GSK’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.32, and their Forward P/E ratio for the next fiscal year is 9.65. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.23 while its Price-to-Book (P/B) ratio in mrq is 4.32. Its current Enterprise Value per Revenue stands at 6.281 whereas that against EBITDA is 21.223.
Stock Price History:
The Beta on a monthly basis for GSK is 0.47, which has changed by 0.27714133 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, GSK has reached a high of $47.16, while it has fallen to a 52-week low of $31.72. The 50-Day Moving Average of the stock is 9.84%, while the 200-Day Moving Average is calculated to be 19.38%.
Shares Statistics:
The stock has traded on average 4.86M shares per day over the past 3-months and 7229200 shares per day over the last 10 days, according to various share statistics. A total of 2.01B shares are outstanding, with a floating share count of 2.01B. Insiders hold about 0.00% of the company’s shares, while institutions hold 19.17% stake in the company. Shares short for GSK as of 1760486400 were 13334110 with a Short Ratio of 2.74, compared to 1757894400 on 10975023. Therefore, it implies a Short% of Shares Outstanding of 13334110 and a Short% of Float of 0.66000004.
Dividends & Splits
In the trailing 12 months, GSK’s forward annual dividend rate was 0.64, compared to 1.64 this year. Against a Trailing Annual Dividend Yield of 0.013669372. The stock’s 5-year Average Dividend Yield is 4.66. The current Payout Ratio is 94.89% for GSK, which recently paid a dividend on 2025-08-15 with an ex-dividend date of 2025-11-14. Stock splits for the company last occurred on 2022-07-22 when the company split stock in a 1226:1000 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is $1.2, with high estimates of $1.2 and low estimates of $1.2.
Analysts are recommending an EPS of between $4.56 and $4.41 for the fiscal current year, implying an average EPS of $4.48. EPS for the following year is $4.85, with 4.0 analysts recommending between $5.15 and $4.63.
Revenue Estimates
7 analysts predict $8.41B in revenue for. The current quarter. It ranges from a high estimate of $8.57B to a low estimate of $8.17B. As of. The current estimate, GSK Plc ADR’s year-ago sales were $8.12BFor the next quarter, 7 analysts are estimating revenue of $7.81B. There is a high estimate of $7.81B for the next quarter, whereas the lowest estimate is $7.81B.
A total of 18 analysts have provided revenue estimates for GSK’s current fiscal year. The highest revenue estimate was $32.84B, while the lowest revenue estimate was $32.09B, resulting in an average revenue estimate of $32.44B. In the same quarter a year ago, actual revenue was $31.38BBased on 13 analysts’ estimates, the company’s revenue will be $34.32B in the next fiscal year. The high estimate is $35.67B and the low estimate is $33.43B.
